Welcome to our dedicated page for Moolec Science SA Ordinary Shares news (Ticker: MLEC), a resource for investors and traders seeking the latest updates and insights on Moolec Science SA Ordinary Shares stock.
Moolec Science SA (NASDAQ: MLEC) is a pioneering science-based food ingredient company that leads the way in Molecular Farming technology, an innovative method for producing animal proteins in plants. Moolec’s mission is to create unique, sustainable food ingredients by engineering plants with animal protein genes. The company focuses on upgrading the taste, nutrition, and affordability of alternative protein products, thereby contributing to a more sustainable and equitable food system.
Moolec's core technology integrates the agronomic efficiency of widely used crops like soybean, safflower, and pea with the functionality of animal proteins, offering a groundbreaking approach to food production. The company's recent achievements include the development of Piggy Sooy™, a soybean platform that produces high amounts of pork protein, significantly enhancing the efficiency of protein production in plants.
With its disruptive innovations, Moolec has established a strong patent portfolio, consisting of over 25 patents (both granted and pending). These patents protect the company's proprietary methods and products, which have applications across various industries, including pharmaceuticals, cosmetics, and diagnostics. Moolec operates internationally, with a diverse team of Ph.D.s and food industry experts working in the United States, Europe, and South America.
Moolec has also recently announced agreements to issue convertible notes totaling approximately $30 million to strategic partners, which will further bolster its financial position and accelerate its R&D and commercialization efforts. Additionally, the company's breakthroughs in regulatory approvals, such as the USDA-APHIS review of Piggy Sooy™, underscore its leadership in the biotech landscape.
Moolec’s forward-looking strategy includes ongoing partnerships, like the one with Grupo Insud and Bioceres Crop Solutions, which provide both financial and operational support. These collaborations are pivotal in advancing Moolec's mission to redefine animal protein production for the betterment of global food security and sustainability.
Moolec Science SA (NASDAQ:MLEC) has announced the upcoming harvest of its genetically engineered plant-grown products GLASO™ and Piggy Sooy™ in October 2024. The GLASO™ campaign in Idaho covers 600 acres and is expected to yield 300-400 tons of high-GLA safflower seeds. Moolec has secured an offtake agreement with a major global CPG company for GLASO™, targeting the US market in 2025. Piggy Sooy™ field trials are being conducted in Ohio, Missouri, and Iowa for product development, seed increase, and regulatory data gathering. Moolec recently obtained USDA-APHIS approval for Piggy Sooy™ cultivation, marking a significant milestone in Molecular Farming. The company aims to provide sustainable solutions in agriculture and biotechnology, with Piggy Sooy™ potentially producing pork meat proteins equivalent to 10 pigs per acre while reducing environmental impact.
Moolec Science SA (NASDAQ:MLEC) has signed a three-year offtake agreement with a major global consumer packaged goods and pet food company for its GLASO™ product, a high-GLA safflower oil. The agreement covers US territory with an initial estimated volume of 50 tons for 2025. GLASO™ contains almost 3 times more GLA than conventional sources, making it the most concentrated GLA oil available.
Moolec has also secured agreements with farmers for safflower cultivation and an industrial partner for downstream processing, ensuring a controlled supply chain. This milestone demonstrates Moolec's ability to scale production and meet growing demand for sustainable nutritional ingredients.
Moolec Science (NASDAQ:MLEC) has released its business update for the third quarter of Fiscal Year 2024, ending March 31, 2024. Key highlights include the USDA-APHIS regulatory approval of their patented soybean product, Piggy Sooy™, and progress in the GLASO™ safflower platform. Financially, normalized revenues and other income increased by approximately $1.3 million year-over-year due to the consolidation of the soy-protein ingredient business. However, R&D, administrative, and other expenses rose to $2.3 million, a 68% year-over-year increase, largely due to non-cash items. Operational cash utilization for the quarter was around $2.6 million, with $1.4 million allocated to reducing accounts payable. CEO Gastón Paladini and CFO José López Lecube expressed optimism about the company's achievements and future prospects.
Moolec Science (NASDAQ: MLEC), a company specializing in Molecular Farming to produce animal proteins in plants, will release its Third Quarter Fiscal Year 2024 Business Update on May 30, 2024, before market opening.
CEO Gastón Paladini, CFO José López Lecube, and CSO Amit Dhingra will host a live conference call at 08:30 a.m. ET the same day, followed by a Q&A session. The conference call will feature a presentation available during the webcast, with a replay and PDF version accessible two hours post-event on the company's Investor Relations website.
Moolec Science SA (NASDAQ: MLEC) announced the granting of a patent in the United States for its SPC2 product produced in safflower with Molecular Farming technology. This patent provides exclusivity until 2041, showcasing Moolec's innovative approach in the industrial biotech sector. The technology involves safflower plants engineered with DNA sequences to enhance bovine chymosin expression, paving the way for new proteins and products. Moolec's Chief Science Officer highlighted the significance of this patent in expanding opportunities for the company's safflower platform and driving innovation in sustainable biotechnology.
FAQ
What is the current stock price of Moolec Science SA Ordinary Shares (MLEC)?
What is the market cap of Moolec Science SA Ordinary Shares (MLEC)?
What is Moolec Science SA?
What is Molecular Farming?
What is Piggy Sooy™?
Where does Moolec operate?
What are Moolec’s recent financial achievements?
What are some of Moolec's strategic partnerships?
What industries can benefit from Moolec's technology?
What recent regulatory approval has Moolec achieved?
How many patents does Moolec hold?
What is the mission of Moolec Science SA?
